Full-year revenues increased 65% to $44.5 million
Investments in technology and staff position Sensus for growth in 2023 and beyond
Conference call begins at 4:30 p.m. Eastern time today
BOCA RATON, Fla., Feb. 09, 2023 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions (Company or Sensus), announces financial results for the three and 12 months ended December 31, 2022.
Highlights from the fourth quarter of 2022 and recent weeks include the following (all comparisons are with the fourth quarter of 2021, unless otherwise indicated):
